The Cytogenetics Shared Resource provides individual Cancer Center investigators with expertise in the conventional and molecular cytogenetic analyses of human and mouse tumor cell lines, somatic cell lines and tumor tissues, as well as mouse peripheral blood and tail DNA samples. This Resource offers services for conventional (e.g., karyotyping of cell lines) and molecular (e.g., FISH, fiber FISH, quantitative FISH) analyses of cells and tissues that would otherwise be difficult (i.e., expensive), if not impossible, to obtain outside this institution. In addition, services are tailored to meet the needs of individual investigators when and where appropriate. For example, new molecular cytogenetic assays have been incorporated into the core to meet the needs of the investigators within the Solid Malignancy and Molecular Oncology Programs of the Cancer Center. Examples include fiber FISH, or DIRVISH, which is a new application of fluorescence in situ hybridization that utilizes linearized free chromatin as a hybridization target. This technique has the capacity to detect very small changes in the genome (i.e., less than 5 kb), and was recently used to detect deletions within the CASP8 gene in a neuroblastoma cell line with a small homozygous deletion. Quantitative FISH was incorporated into the facility in order to determine the copy number of a BAC transgene within specific transgenic mice for investigators in the Solid Malignancy, Molecular Oncology and Neurobiology and Brain Tumor Programs. This method facilitates the quantitative assessment of copy-number of a BAC transgene when compared with the endogenous gene locus. It has also been used to genotype (heterozygous vs. homozygous) approximately 160 of these transgenic mice by using a novel method of FISH using tail cells as the hybridization target. A FISH assay was recently incorporated into the core facility to analyze the length of telomeres in cell lines derived from various genetically altered mice. The fiber FISH and telomere FISH assays were developed to meet the needs of investigators in the Molecular Oncology, Solid Malignancy, and Hematopoietic Malignancy Programs. The telomere FISH assay is being used to accurately analyze changes in telomere length of chromosomes from tumor cells in a ploidy-independent manner. Recently, this Shared Resource has also added flow FISH to the list of services provided to Cancer Center investigators. Thus far, the Programs in Molecular Oncology, Developmental Therapeutics for Solid Malignancies, Hematopoietic Malignancies, as well as Neurobiology and Brain Tumors, have been able to benefit from the addition of this new methodology. This method has been used to determine the length of telomeres in the peripheral blood cells of patients who have undergone chemotherapy in order to determine the magnitude of the shortening of the telomeres resulting from this treatment. Thus, the Cytogenetics Shared Resource offers not only conventional analysis, but meets the needs of the various investigators within the Cancer Center to continue providing first-rate service that often plays a role in the obtaining of individual RO1 grants, and/or their renewals, for Cancer Center investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA021765-25
Application #
6600420
Study Section
Project Start
2002-06-20
Project End
2007-02-28
Budget Start
Budget End
Support Year
25
Fiscal Year
2002
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Devine, Katie A; Mertens, Ann C; Whitton, John A et al. (2018) Factors associated with physical activity among adolescent and young adult survivors of early childhood cancer: A report from the childhood cancer survivor study (CCSS). Psychooncology 27:613-619
Matreyek, Kenneth A; Starita, Lea M; Stephany, Jason J et al. (2018) Multiplex assessment of protein variant abundance by massively parallel sequencing. Nat Genet 50:874-882
Hazlitt, Robert A; Min, Jaeki; Zuo, Jian (2018) Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss. J Med Chem 61:5512-5524
Hoehn, Mary Ellen; Calderwood, Julie; Gannon, Edwin et al. (2018) Ocular complications in a young pediatric population following bone marrow transplantation. J AAPOS 22:102-106.e1
Zimmerman, Mark W; Liu, Yu; He, Shuning et al. (2018) MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discov 8:320-335
Hammill, Jared T; Bhasin, Deepak; Scott, Daniel C et al. (2018) Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem 61:2694-2706
Li, Yanfeng; Bakke, Jesse; Finkelstein, David et al. (2018) HNRNPH1 is required for rhabdomyosarcoma cell growth and survival. Oncogenesis 7:9
Khan, Raja B; Merchant, Thomas E; Sadighi, Zsila S et al. (2018) Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. J Neurooncol 136:379-384
Ma, Xiaotu; Liu, Yu; Liu, Yanling et al. (2018) Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555:371-376
Broniscer, Alberto; Jia, Sujuan; Mandrell, Belinda et al. (2018) Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer 65:e27035

Showing the most recent 10 out of 6764 publications